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INTRODUCTION
Due to recent advances in endoscopic technology, early gastrointestinal cancers, which are defined as those that invade no more deeply than the submucosa, are treated endoscopically [1] [2] [3] .
Endoscopic submucosal dissection (ESD) or local tumor excisions that allow en bloc resection, which lead to more precise histological evaluation and more potential for cure, are considered clinically relevant for early gastrointestinal cancer. A complete local resection of in situ or intramucosal tumor is acceptable as a curative treatment due to little risk of lymph node metastasis [4] [5] [6] [7] . However, lymph node metastasis is typically found in submucosal invasive gastrointestinal cancer such as esophageal, gastric and colorectal cancer, at an approximate frequency of greater than 10% [8] [9] [10] [11] . Since it is hard to determine submucosally invaded lesions with the risk of lymph node metastasis without pathological evaluation, these patients are treated surgically to remove possibly metastasized lymph nodes, even though primary early gastrointestinal cancer itself is technically resectable with ESD. This means that most submucosal invasive gastrointestinal cancer patients, who are node-negative, routinely undergo unnecessary surgery. Thus, a less invasive way to selectively treat lymph node metastasis would benefit these patients by allowing them to avoid a prophylactic surgery.
Sentinel lymph node metastasis represents the initial spread of malignant tumors from the primary site. Metastatic lymph nodes as well as migrating tumor cells in the draining lymph vessels have to be treated to prevent recurrence and, therefore, anticancer agents that spread over the regional lymphatic area are required. For sentinel lymph node mapping, submucosal injection of a visible dye such as methylene blue or indocyanine green (ICG) allows an adequate regional diffusion in the lymphatic area 12 . It has also been reported that human adenovirus can be effectively transported into the lymphatic circulation in murine models 13, 14 . Oncolytic viruses that selectively replicate in tumor cells and lyse infected cells have been developed as anticancer agents [15] [16] [17] [18] . These viruses are designed to induce virusmediated lysis of infected cells after selective viral replication within the tumor cells.
In the present study, we evaluated whether a telomerase-dependent, tumor-killing replicating adenoviral agent (OBP-301) that was administered submucosally prior to the primary tumor resection could purge lymph node metastasis in an orthotopic early rectal cancer xenograft model with spontaneous lymph node metastasis. The steps of this procedure mimic the procedures of ESD for gastrointestinal cancer in the clinical setting. The successful elimination of sentinel lymph node metastasis indicates that concurrent submucosal injection of OBP-301 and endoscopic tumor removal might be an epoch-making therapeutic alternative to prophylactic surgery for patients with submucosally invaded gastrointestinal cancer.
RESULTS

In vitro cytopathic effect of the virus towards human colorectal cancer cells
OBP-301 (Telomelysin) is an attenuated adenovirus that drives the E1A and E1B genes under the human telomerase reverse transcriptase (hTERT) promoter and is capable of killing human epithelial as well as mesenchymal malignant cells in a telomerase-dependent manner We previously reported that no apparent CPE was observed in normal human cell lines after OBP-301 infection 19 .
Sentinel lymph node metastasis in an orthotopic rectal cancer xenograft model
A submucosally invaded early rectal tumor model was established by inoculating HCT-116-GFP or Colo205-GFP human colorectal cancer cells orthotopically into athymic nu/nu mice. by detection of cancer cell-derived GFP signals in the lymph node (Figure 2c, d) . A series of experiments confirmed that percent metastasis to the sentinel lymph node on day 7 after tumor cell inoculation in mice implanted with HCT-116-GFP and Colo205-GFP was 78.5%
(33/42) and 62.5% (25/40), respectively.
Viral trafficking to lymph nodes and selective replication in metastatic foci
The lymphatic system is a major pathway for the metastatic spread of cancers as well as for the regional distribution of biological mediators including fluids, proteins, chemicals, cells and drugs. Prior to injection of virus, we first assayed the ability of an injected solution to reach the draining lymph nodes. For this purpose, we investigated the diffusion pattern of a 1% indigo carmine blue dye solution that was peritumorally injected into the submucosal space of the rectum in the orthotopic rectal cancer xenografts. Intense blue staining was detected in regional lymph nodes as early as 1 minute after injection of the dye, indicating that an injected solution could rapidly enter the lymphatics and spread to the draining lymph nodes (Supplementary Figure S4) .
To verify that virus could move to regional lymph nodes and further infect tumor cells in these nodes after peritumoral injection into the submucosal space of the mouse rectum, we 
Virus-mediated biological ablation of metastatic foci in regional lymph nodes
We next examined whether peritumoral submucosal injection of OBP-301 followed by primary tumor resection could ablate lymph node metastasis in the orthotopic submucosally invaded rectal cancer xenografts. Seven days after inoculation with HCT-116-GFP human colorectal cancer cells, mice that had successfully established GFP-expressing lymph node metastasis were selected by fluorescence imaging at laparotomy, and were further studied confirmed that virally purged lymph nodes were relapse-free (data not shown). These results suggest that submucosal pre-injection of OBP-301 followed by primary tumor resection sustainably prevented metastatic tumor relapse over a long period.
DISCUSSION
The standard of care for treatment of intramucosal neoplastic lesions of the esophagus, stomach and colorectum is now a patient-friendly ESD that enables en-block resection of cancerous lesions regardless of size, since statistically intramucosal tumors rarely metastasize to the lymph node 2,23-25 . However, when tumors penetrate slightly deeper into the submucosal layer, the incidence of nodal metastasis appears to increase significantly and, therefore, these patients are referred for complementary surgery with regional lymph node dissection 10, 11, 26 . Here, we describe a more effective and less invasive biological management for lymphatic metastasis that uses the telomerase-specific, replication-selective, oncolytic adenovirus OBP-301 and that employs submucosally invaded early rectal cancer xenograft mouse models. In detail, in place of surgical lymphadenectomy we used a solution containing a tumor-killing virus as a submucosal cushioning agent before resection of the primary tumor.
From a clinical viewpoint, this new, simple, and robust strategy is a more realistic and promising bench-to-bedside translation than prophylactic surgery for ablation of potential lymph node metastases in early gastrointestinal cancer patients.
Overexpression of telomerase, which is a ribonucleoprotein enzyme complex that is responsible for the complete replication of chromosomal ends, is thought to play a key role in the infinite reproduction of cancer cells 27, 28 . We constructed a telomerase-specific replicating adenovirus, OBP-301, in which the hTERT promoter element drives expression of the E1 genes that are essential for adenoviral replication 19 . As hTERT is the catalytic subunit of telomerase, OBP-301 shows tumor-specific intracellular viral replication that is regulated by hTERT transcriptional activity in human tumors [19] [20] [21] . Viral yields correlated well with hTERT mRNA expression in human cancer cell lines 13, 22 , although there was no significant correlation between hTERT mRNA expression and the cytopathic activity of OBP-301 21 . It has been reported that the hTERT promoter could be applied to induction of transgene expression in syngeneic tumors in mice 29 . We also previously confirmed that a hTERT promoter-driven tumor killing adenovirus could replicate in murine colorectal cancer cells such as Colon-26 in vitro and in vivo 13 . These findings suggest that OBP-301 can replicate in murine as well as in human tissues, when telomerase is activated. Thus, the submucosally invaded orthotopic early rectal cancer xenograft model, which develops spontaneous lymph node metastasis, is a suitable translational animal model for simulation of the in vivo behavior patterns of this virus.
The lymphatic system plays a crucial role in initial lymphatic dissemination of human cancer cells and subsequent development of lymph node metastases. In addition to the preexisting lymphatic network, it is well known that new lymphatic vessels can be generated from pre-existing ones by tumor-secreting mediators such as vascular endothelial growth factors (VEGF) and angiopoietins 30 . This tumor-induced lymphangiogenesis is often associated with structural and functional abnormalities of the lymphatic vasculature, which are analogous to the aberrations of tumor blood vessels 31 . Although lymphatic vessels began to show abnormalities even in the early stages of carcinogenesis, advanced tumors have more compressed and nonfunctional lymphatics presumably due to tumor infiltration 32 . The lymphatic system also provides a route for the delivery of therapeutic molecules including biological agents. We have shown that OBP-301 virus injected into the space under the orthotopically xenografted early rectal cancer could easily reach regional lymph nodes with normal lymphatic flow; however, a complex and impaired lymphatic network in more advanced tumors might disturb an optimal distribution of therapeutics into the regional lymphatic area. Therefore, early-stage cancer patients who potentially have micro-lymph node metastasis might be an appropriate target for locoregional therapy through the lymphatic system.
The standard procedures for ESD, which include marking outside the lesion, injection of various submucosal solutions, circumferential incision into the mucosa and direct dissection of the submucosal layer, have been established 33 . As submucosal dissection with simultaneous hemostasis causes destruction of the normal lymphatic network, administration of therapeutic molecules prior to complete removal of neoplastic lesions is the ideal time to deliver these molecules over the locoregional lymphatic area including the sentinel lymph nodes. The use of submucosal injection to isolate the target lesion is considered to be essential for a successful ESD. In addition to normal saline, many types of solutions such as glycerol, dextrose water and hyaluronic acid have been applied clinically 34 . The key aspect of our study is that a solution containing tumor-killing virus was used as a submucosal cushion and, therefore, the virus delivery could be easily adapted to the standard ESD procedures.
Moreover, we found that submucosally injected dye could rapidly enter the lymphatic flow and spread to the draining lymph nodes, indicating a potential for extension of the purging effects of the viruses beyond the sentinel lymph nodes. investigator-driven clinical study of OBP-301 in combination with radiotherapy for esophageal cancer is currently ongoing in our hospital without any severe dose-limiting toxicity. Therefore, a 2-log-higher dose of OBP-301 could be available in humans for monotherapy as well as for combination therapy. In addition, analysis of autopsied patients in our previous trial showed that a replication-defective adenoviral vector can persist in proximal lymph nodes for approximately 5 months after intratumoral injection 37 . Indeed, although metastatic lymph nodes grew in mice that received cisplatin, which is a broadly used anticancer drug, no recurrence was observed in OBP-301-treated mice in which lymph node metastasis had been eradicated, suggesting a long-term surveillance activity of OBP-301.
In conclusion, we have demonstrated that the telomerase-specific replication-selective adenovirus OBP-301 can be delivered into neoplastic foci in regional lymph nodes after submucosal injection at the time of primary tumor dissection and effectively ablate lymph node metastasis in an early gastrointestinal cancer model. We previously reported that metastatic tumor cells in the lymph nodes apparently unexpectedly increased after surgical removal of invasive rectal tumors, presumably due to excessive damage to the host 38 ;
however, less-invasive submucosal dissection of tumors did not affect the incidence of lymph node metastasis. The administration of OBP-301 by inclusion in the standard ESD procedures is a revolutionary treatment option for early gastrointestinal cancer patients, which avoids impairing the quality of life that occurs due to surgery for prophylactic lymphadenectomy.
Moreover, clinical morbidity of lymphedema particularly in breast cancer axillary node dissection is of significant consequence. Our strategy may have a potential for clinical advantages in other oncologic fields. Figure S1b) . The E1A-deleted adenovirus vector lacking a cDNA insert (dl312) was also used as a control vector. Viruses were purified by ultracentrifugation using CsCl step gradients. Viral titers were determined by a plaqueforming assay using 293 cells, and the virus was stored at −80 °C. 
MATERIALS AND METHODS
Cell
Cell viability assay. HCT-116-GFP and
Animal experiments. The experimental protocol was approved by the Ethics Review
Committee for Animal Experimentation of our institution. Six to eight-week old female BALB/c nude mice (Clea Japan Tokyo, Japan) were used in this study. All animal procedures were performed under anesthesia using s.c. administration of a ketamine mixture (100 mg/kg ketamine HCL, 7 mg/kg xylazine HCL).
Mice For pathological evaluation of lymph node metastasis, mice were sacrificed and all para-aortic or iliac lymph nodes were isolated and were stained with hematoxylin and eosin or were immunohistochemically analyzed.
In vivo fluorescence imaging. To monitor the outgrowth of the primary tumors and the metastatic lymph nodes, in vivo fluorescence images were taken at laparotomy using an
Olympus SZX16 microscope and a DP71 camera (Olympus, Tokyo, Japan). Images were processed for contrast and brightness with the use of Adobe Photoshop software (Adobe).
Green fluorescence intensity was analyzed using Image J software for the quantification of lymph node metastasis. For long-term evaluation, abdominal images were serially obtained and quantified.
Quantitative real-time PCR analysis. We previously established a highly sensitive quantitative assay that targets a human-specific Alu sequence in order to quantify lymph node metastasis in mice. We used this previously described assay in the present study to measure the numbers of metastatic human tumor cells in mouse lymph nodes 38 . Briefly, genomic DNA was extracted from harvested lymph node tissues and analyzed by the quantitative realtime PCR assay using a set of human Alu primers (sense: 5'-CTG AGG TCA GGA GTT CGA G-3'; and antisense: 5'-TCA AGC GAT TCT CCT GCC-3'). We also amplified the mouse GAPDH genomic DNA sequence using mouse GAPDH primers (sense: 5'-CCA CTC TTC CAC CTT CGA T-3'; and antisense: 5'-CAC CAC CCT GTT GCT GTA-3'). The number of metastatic tumor cells in mouse lymph nodes is defined as the Alu/GAPDH ratio relative to that of the PBS-treated sample (PBS = 1).
Immunohistochemistry. For histological studies, rectal tumors and lymph nodes were removed and placed into buffered formalin for 24 h at room temperature. All of the tissues were subsequently processed through alcohol dehydration and paraffinization. Tissues were embedded in paraffin and sectioned for hematoxylin-eosin staining and also for immunohistochemical examination. After deparaffinization and rehydration, antigen retrieval was performed by microwave irradiation in 10 mM citrate buffer (pH 6.0). Following quenching of endogenous tissue peroxidase, tissue sections were incubated with mouse antiadenovirus type 5 E1AmAb (BD Biosciences). The sections were then incubated using the Histofine Mouse Stain Kit (Nichirei Biosciences, Tokyo, Japan) for 10 min at 25 °C to block nonspecific reactivity with mouse serum. Immunoreactive signals were visualized by using a 3,39-diaminobenzidine tetrahydrochloride solution, and the nuclei were counterstained with hematoxylin. Signals were viewed under a microscope (BX50; Olympus).
Statistical analysis.
We used Student's t-test to identify statistically significant differences between groups. All data are expressed as means ± SD. P values less than 0.05 were considered statistically significant.
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